Stock Price Prediction

Anthony Vendetti from Maxim Group has reiterated a Buy rating on DXR stock with a price target of $22.00, citing strong financial performance, increased diagnostic kit sales, and new government contracts as key growth drivers. Additionally, the anticipation of a next-generation BVA device, expected to be smaller and faster with potential FDA approval, supports bullish sentiment. The recent acquisition of exclusive rights to Volumex, Megatope, and Glofil further strengthens Daxor's market position and earnings potential.

DXR stock closed at $7.685 on January 31, 2025, with a 5.12% drop. The bearish view stems from weak technical indicators, including an RSI of 40.52, signaling oversold conditions, and a MACD showing negative momentum. Additionally, the price is below key moving averages (SMA 20: $8.07), suggesting continued downward pressure.